Display options
Cite
Neou E, Michail G, Tsakris A, et al. Virulence of Acinetobacter baumannii Exhibiting Phenotypic Heterogeneous Growth against Meropenem in a Murine Thigh Infection Model. Antibiotics (Basel). 2013;2(1):73-82doi: 10.3390/antibiotics2010073.
Neou, E., Michail, G., Tsakris, A., & Pournaras, S. (2013). Virulence of Acinetobacter baumannii Exhibiting Phenotypic Heterogeneous Growth against Meropenem in a Murine Thigh Infection Model. Antibiotics (Basel, Switzerland), 2(1), 73-82. https://doi.org/10.3390/antibiotics2010073
Neou, Evangelia, et al. "Virulence of Acinetobacter baumannii Exhibiting Phenotypic Heterogeneous Growth against Meropenem in a Murine Thigh Infection Model." Antibiotics (Basel, Switzerland) vol. 2,1 (2013): 73-82. doi: https://doi.org/10.3390/antibiotics2010073
Neou E, Michail G, Tsakris A, Pournaras S. Virulence of Acinetobacter baumannii Exhibiting Phenotypic Heterogeneous Growth against Meropenem in a Murine Thigh Infection Model. Antibiotics (Basel). 2013 Mar 11;2(1):73-82. doi: 10.3390/antibiotics2010073. PMID: 27029293; PMCID: PMC4790299.
Copy Download .nbib Format: NLM
Share it on

Antibiotics (Basel). 2013 Mar 11;2(1):73-82. doi: 10.3390/antibiotics2010073.

Virulence of Acinetobacter baumannii Exhibiting Phenotypic Heterogeneous Growth against Meropenem in a Murine Thigh Infection Model.

Antibiotics (Basel, Switzerland)

Evangelia Neou, George Michail, Athanassios Tsakris, Spyros Pournaras

Affiliations

  1. Department of Microbiology, Medical School, University of Thessaly, Larissa 41110, Greece. [email protected].
  2. Department of Microbiology, Medical School, University of Thessaly, Larissa 41110, Greece. [email protected].
  3. Department of Microbiology, Medical School, University of Athens, Athens 11527, Greece. [email protected].
  4. Department of Microbiology, Medical School, University of Thessaly, Larissa 41110, Greece. [email protected].
  5. Department of Microbiology, Medical School, University of Athens, Athens 11527, Greece. [email protected].

PMID: 27029293 PMCID: PMC4790299 DOI: 10.3390/antibiotics2010073

Abstract

Acinetobacter baumannii may exhibit phenotypic heterogeneous growth under exposure to antibiotics. We investigated the in vitro characteristics of A. baumannii isolates grown heterogeneously in the presence of meropenem and their virulence evaluated in experimental infections treated with meropenem. Five clinical A. baumannii isolates and the respective heterogeneously grown subpopulations were tested by agar dilution minimum inhibitory concentration (MIC) testing, pulsed field gel electrophoresis (PFGE), population analysis using meropenem and growth curves. The virulence of isolates and the therapeutic efficacy of three meropenem dosing schemes was evaluated in a neutropenic murine thigh infection model. The clinical isolates were meropenem-susceptible (MICs 1 to 4 mg/liter) and exhibited three distinct PFGE patterns. In all clinical isolates, population analysis yielded heterogeneously grown colonies. After seven subcultures in antibiotic-free media, resistant MIC levels were retained in two isolates (heteroresistant), while three isolates were reversed to susceptible MICs (persisters). Clinical isolates and heterogeneous subpopulations had similar growth rates. The heterogeneously grown A. baumannii subpopulations had reduced virulence, killing considerably fewer animals than the respective clinical isolates without treatment. The meropenem treatment outcome was similar in infections caused by the clinical and the heterogeneous isolates, irrespective to their MICs. In vitro meropenem exposure induces phenotypic heterogeneous growth in A. baumannii. Compared with the parental clinical isolates, the heterogeneously grown subpopulations exhibited lower virulence, killing fewer mice and responding equally to meropenem treatment, despite their higher MICs.

Keywords: experimental infections; heteroresistance; persisters; virulence

References

  1. Science. 2004 Sep 10;305(5690):1622-5 - PubMed
  2. J Antimicrob Chemother. 2008 Jan;61(1):169-72 - PubMed
  3. Antimicrob Agents Chemother. 2005 Nov;49(11):4485-91 - PubMed
  4. J Clin Microbiol. 2009 Dec;47(12):4055-9 - PubMed
  5. J Clin Microbiol. 1995 Sep;33(9):2233-9 - PubMed
  6. J Antimicrob Chemother. 2008 Dec;62(6):1326-31 - PubMed
  7. J Antimicrob Chemother. 2004 Feb;53(2):393-5 - PubMed
  8. Diagn Microbiol Infect Dis. 2009 Aug;64(4):427-33 - PubMed
  9. Proteomics. 2009 Mar;9(6):1632-45 - PubMed
  10. Antimicrob Agents Chemother. 1998 Sep;42(9):2375-9 - PubMed
  11. Clin Infect Dis. 2006 Mar 1;42(5):692-9 - PubMed
  12. J Antimicrob Chemother. 2003 Dec;52(6):1046-7 - PubMed
  13. Clin Infect Dis. 2006 Sep 1;43 Suppl 2:S49-56 - PubMed
  14. Int J Antimicrob Agents. 2011 Apr;37(4):302-8 - PubMed
  15. Int J Antimicrob Agents. 2012 Jun;39(6):472-7 - PubMed
  16. J Antimicrob Chemother. 2005 Jun;55(6):1055-6 - PubMed
  17. J Antimicrob Chemother. 2012 Apr;67(4):928-32 - PubMed
  18. Clin Infect Dis. 2005 Sep 15;41(6):848-54 - PubMed
  19. Antimicrob Agents Chemother. 2005 Apr;49(4):1483-94 - PubMed
  20. Antimicrob Agents Chemother. 2008 Jan;52(1):351-2 - PubMed
  21. J Microbiol Methods. 2003 Sep;54(3):411-8 - PubMed
  22. J Antimicrob Chemother. 2010 Sep;65(9):1984-90 - PubMed
  23. J Antimicrob Chemother. 2006 Mar;57(3):557-61 - PubMed
  24. J Clin Microbiol. 2006 Nov;44(11):4189-92 - PubMed

Publication Types